Physician profile
Charles Joseph Lane
NPI 1699983353
$1,413,720.91
in general payments reported to CMS, 2019-2025
34 companies · $261K in 2025
The $261K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160K · 2020: $80K · 2021: $231K · 2022: $180K · 2023: $241K · 2024: $261K · 2025: $261K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $628K · Travel and Lodging: $73K · Consulting Fee: $37K · Food and Beverage: $25K · Education: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $627,710.14 |
| Travel and Lodging | $73,431.42 |
| Consulting Fee | $36,720.00 |
| Food and Beverage | $24,972.43 |
| Education | $600.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $552,841.86 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $299,078.51 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $256,941.37 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $117,369.07 | 2019-2023 | Airduo Digihaler |
| Glaxosmithkline, LLC. | $98,019.96 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $55,130.62 | 2019-2025 | Xolair |
| Amgen INC. | $11,842.58 | 2022-2025 | Tezspire |
| Pfizer INC. | $7,077.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $5,889.19 | 2019-2025 | |
| Optinose US, INC. | $3,025.89 | 2020-2025 | |
| Incyte Corporation | $1,783.39 | 2022-2025 | |
| Blueprint Medicines Corporation | $1,460.31 | 2020-2024 | Ayvakit |
| Genentech, INC. | $511.41 | 2020-2025 | Xolair |
| Csl Behring | $508.40 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Sanofi-Aventis U.S. LLC | $450.00 | 2019-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $298.09 | 2025 | Neffy |
| Kaleo, INC. | $252.20 | 2020-2022 | |
| Grifols USA, LLC | $233.48 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $231.53 | 2020-2025 | Takhzyro, Glassia, Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.47 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $203.40 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $65.51 | 2019-2024 | Ruconest |
| Alk-Abello, INC | $53.07 | 2019 | |
| Ionis Pharmaceuticals, INC. | $36.53 | 2025 | Donidalorsen, Dawnzera |
| Aimmune Therapeutics, INC. | $33.41 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $31.48 | 2022 | |
| Verona Pharma, INC. | $22.88 | 2025 | Ohtuvayre |
| Horizon Therapeutics Plc | $21.00 | 2020 | |
| Shire North American Group INC | $16.09 | 2019 | |
| Galderma Laboratories, L.P. | $15.47 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $14.15 | 2023 | |
| Biocryst Pharmaceuticals, INC. | $13.44 | 2020 | |
| Mylan Specialty L.P. | $11.62 | 2020 | |
| Circassia INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.